Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 86.5 2.25% 1.90
ALNY closed up 2.25 percent on Friday, September 20, 2019, on 1.78 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ALNY trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
NR7 Range Contraction 2.25%
Upper Bollinger Band Walk Strength 2.25%
Slingshot Bullish Bullish Swing Setup 1.18%
Stochastic Reached Overbought Strength 1.18%
Upper Bollinger Band Walk Strength 1.18%
Overbought Stochastic Strength 1.18%
Upper Bollinger Band Touch Strength 1.18%
Golden Cross Bullish -1.50%
Pocket Pivot Bullish Swing Setup -1.50%

Older signals for ALNY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Hemophilia Huntington's Disease Spinal Muscular Atrophy Treatment Of Hemophilia Alnylam Pharmaceuticals Therapeutic Gene Modulation Hemoglobinopathies Hypercholesterolemia Acute Intermittent Porphyria Deficiency
Is ALNY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 96.08
52 Week Low 60.27
Average Volume 720,213
200-Day Moving Average 79.0508
50-Day Moving Average 79.7636
20-Day Moving Average 83.398
10-Day Moving Average 84.917
Average True Range 3.0113
ADX 18.87
+DI 19.172
-DI 11.6518
Chandelier Exit (Long, 3 ATRs ) 78.9661
Chandelier Exit (Short, 3 ATRs ) 87.5539
Upper Bollinger Band 87.3272
Lower Bollinger Band 79.4688
Percent B (%b) 0.89
BandWidth 9.422768
MACD Line 1.7291
MACD Signal Line 1.6409
MACD Histogram 0.0882
Fundamentals Value
Market Cap 7.93 Billion
Num Shares 91.7 Million
EPS -5.12
Price-to-Earnings (P/E) Ratio -16.89
Price-to-Sales 159.14
Price-to-Book 9.35
PEG Ratio -0.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 90.13
Resistance 3 (R3) 89.96 88.57 89.53
Resistance 2 (R2) 88.57 87.65 88.66 89.32
Resistance 1 (R1) 87.54 87.08 88.06 87.71 89.12
Pivot Point 86.15 86.15 86.41 86.24 86.15
Support 1 (S1) 85.12 85.23 85.64 85.29 83.88
Support 2 (S2) 83.73 84.66 83.82 83.68
Support 3 (S3) 82.70 83.73 83.48
Support 4 (S4) 82.87